Outcomes of Surveillance Protocol of Clinical Stage I Nonseminomatous Germ Cell Tumors-Is Shift to Risk Adapted Policy Justified?

Journal of Urology

Volumn 176, Issue 4, 2006, Pages 1424-1430

  Divrik, Rauf Taner ^a,b   Akdoǧan, Bülent ^b   Özen, Haluk ^b   Zorlu, Ferruh ^a,b  

^a TEPECIK EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

recurrence; risk factors; testicular neoplasms

Indexed keywords

ALPHA FETOPROTEIN; TUMOR MARKER;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER INVASION; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CHILD; DISEASE FREE SURVIVAL; EMBRYO; EMBRYONAL CARCINOMA; FOLLOW UP; GERM CELL TUMOR; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RISK FACTOR; SURGICAL TECHNIQUE;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASMS, GERM CELL AND EMBRYONAL; ORCHIECTOMY; POPULATION SURVEILLANCE; PROGRAM EVALUATION; RETROSPECTIVE STUDIES; RISK FACTORS; TESTICULAR NEOPLASMS; TREATMENT OUTCOME;

EID: 33748105665     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.06.012     Document Type: Article

References (20)

1. Stephenson A.J., and Sheinfeld J. The role of retroperitoneal lymph node dissection in the management of testicular cancer. Urol Oncol 22 (2004) 225
2. Culine S., Theodore C., Terrier-Lacombe M.J., and Droz J.P. Primary chemotherapy in patients with nonseminomatous germ cell tumors of the testis and biological disease only after orchiectomy. J Urol 155 (1996) 1296
3. Peckham M.J., Barrett A., Husband J.E., and Hendry W.F. Orchiectomy alone in testicular stage I nonseminomatous germ cell tumors. Lancet 2 (1982) 678
4. Donohue J.P., Thornhill J.A., Foster R.S., Rowland R.G., and Bihrle R. Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989). modifications of technique and impact on ejaculation. J Urol 149 (1993) 237
5. Pizzocaro G., Zanoni F., Milani A., Salvioni R., Piva L., Pilotti S., et al. Orchiectomy alone in clinical stage I nonseminomatous testis cancer. a critical appraisal. J Clin Oncol 4 (1986) 35
6. Freedman L.S., Parkinson M.C., Jones W.G., Oliver R.T., Peckham M.J., Read G., et al. Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet 2 (1987) 294
7. Wishnow K.I., Johnson D.E., Swanson D.A., Tenney D.M., Babaian R.J., Dunphy C.H., et al. Identifying patients with low-risk clinical stage I nonseminomatous testicular tumors who should be treated by surveillance. Urology 34 (1989) 339
8. Sturgeon J.F.G., Jewett M.A.S., Alison R.E., Gospodarowicz M.K., Blend R., Herman S., et al. Surveillance after orchidectomy for patients with clinical stage I nonseminomatous testis tumors. J Clin Oncol 10 (1992) 564
9. Sogani P.C., Perrotti M., Herr H.W., Fair W.R., Thaler H.T., and Bosl G. Clinical stage I testis cancer. long-term outcomes of patients on surveillance. J Urol 159 (1998) 855
10. Roeleveld T.A., Horenblas S., Meinhardt W., Van de Vijver M., Kooi M., and Huinink W.W.T.B. Surveillance can be the standard of care for stage I nonseminomatous testicular tumors and even high risk patients. J Urol 166 (2001) 2166
11. Link R.E., Allaf M.E., Pili R., and Kavoussi L.R. Modeling the cost of management options for stage I nonseminomatous germ cell tumors. a decision tree analysis. J Clin Oncol 23 (2005) 5762
12. Raghavan D., Colls B., Levi J., Fitzharris B., Tattersall M.H., Atkinson C., et al. Surveillance for stage I non-seminomatous germ cell tumours of the testis. the optimal protocol has not yet been defined. Br J Urol 61 (1988) 522
13. Thompson P.I., Nixon J., and Harvey V.J. Disease relapse in patients with stage I nonseminomatous germ cell tumor of the testis on active surveillance. J Clin Oncol 6 (1988) 1597
14. Colls B.M., Harvey V.J., Skelton C.M.A., Frampton P.I., Thompson P.I., Bennett M., et al. Late results of surveillance of clinical stage I nonseminoma germ cell testicular tumours. 17 years' experience in a national study in New Zealand. BJU Int 83 (1999) 76
15. Alexandre J., Fizazi K., Mahe C., Culine S., Droz J.-P., Theodore C., et al. Stage I non-seminomatous germ cell tumours of the testis. identification of a subgroup of patients with a very low risk of relapse. Eur J Cancer 37 (2001) 576
16. Atsu N., Eskicorapçi S., Uner A., Ekici S., Gungen Y., Erkan I., et al. A novel surveillance protocol for stage I nonseminomatous germ cell testicular tumours. BJU Int 92 (2003) 32
17. Heidenreich A., Sesterhenn I.A., Mostofi F.K., and Moul J.W. Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis. Cancer 83 (1998) 1002
18. Cullen M.H., Billingham L.J., Cook J., and Woodroffe C.M. Management preferences in stage I non-seminomatous germ cell tumours of the testis. an investigation among patients, controls and oncologists. Br J Cancer 74 (1996) 1487
19. Böhlen D., Burkhard F.C., Mills R., Sonntag R.W., and Studer U.E. Fertility and sexual function following orchiectomy and 2 cycles of chemotherapy for stage I high risk nonseminomatous germ cell cancer. J Urol 165 (2001) 441
20. Klepp O., Dahl O., Flodgren P., Stierner U., Olsson A.M., Oldbring J., et al. Risk-adapted treatment of clinical stage 1 non-seminoma testis cancer. Eur J Cancer 33 (1997) 1038